SEC Form 4 · accession 0001193125-26-279871
Tango Therapeutics, Inc. · TNGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Director
Period of report
Jun 19, 2026
Accepted (ET)
Jun 23, 2026 · 6:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001819133
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 19, 2026 | A | 5,740 | $0.00 | A | 5,740 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $27.97 | Jun 19, 2026 | A | 35,910 | A | — | Jun 19, 2036 | Common Stock | 35,910 | 35,910 | D |
Explanation of responses
- F1These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- F2This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.